NewsFeed Voices Science Insight Innovation
December, 2025
December 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Extended Low-Dose Apixaban After Provoked VTE: Marc Carrier Spotlights Major NEJM Results
Marc Carrier/X
Aug 31, 2025, 07:23

Extended Low-Dose Apixaban After Provoked VTE: Marc Carrier Spotlights Major NEJM Results

 

Marc Carrier, Professor at Ottawa Hospital Research Institute, has posted on X:

”New in NEJM:
In patients with provoked VTE + enduring risk factors, extended low-dose apixaban (2.5 mg bid ×12 months): reduced recurrent VTE risk by nearly 90% (1.3% vs 10.0%): HR 0.13
Major bleeding was rare (1 pt).”

Find the full study here.

Title: Apixaban for Extended Treatment of Provoked Venous Thromboembolism

Authors: Gregory Piazza, Behnood Bikdeli, Arvind K. Pandey, Darsiya Krishnathasan, Candrika D. Khairani, Antoine Bejjani, Ruth H. Morrison, Heather Hogan, Sina Rashedi, Mariana Pfeferman, Junyang Lou, John Fanikos, Nicole Porio, Lisa Rosenbaum, Piotr Sobieszczyk, Zhou Lan, Marie Gerhard-Herman, Umberto Campia, and Samuel Z. Goldhaber

Low dose apixaban in VTE

 

Stay updated with Hemostasis Today.

Antoine Bejjani Apixaban Arvind K. Pandey Behnood Bikdeli Bleeding Risk Brigham and Women’s Hospital–Harvard Medical School Candrika D Khairani Darsiya Krishnathasan Direct Oral Anticoagulants DOAC eth Israel Deaconess Medical Center Gregory Piazza Health Heather Hogan Hematology Hemostasis Hemostasis Today HI-PRO trial John Fanikos Junyang Lou Lisa Rosenbaum Marc Carrier Mariana Pfeferman Marie Gerhard-Herman Medicine NEJM Nicole Porio Ottawa Hospital Research Institute Piotr Sobieszczyk provoked venous thromboembolism Recurrent VTE Ruth H. Morrison Samuel Z. Goldhaber Sina Rashedi The New England Journal of Medicine thrombosis Umberto Campia University of Pittsburgh Medical Center venous thromboembolism Venous Thrombosis VTE Yale Center for Outcomes Research and Evaluation Zhou Lan
NewsFeed